Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01548638 · ClinicalTrials.gov registry record · Phase 2
Effect of Galantamine on Smoking Abstinence
A Phase 2 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT01548638: Completed Phase 2 study, sponsored by University of Pennsylvania.
NCT01548638 is a Phase 2 study that has completed, run by University of Pennsylvania. The registered enrollment target is 13 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01548638, a Phase 2 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
This is a preliminary open-label study to determine whether a medication called galantamine (Brand Name: Razadyne) will help smokers quit and whether it reduces cognitive problems that smokers experience during a quit attempt.
Interventions
- DRUG Galantamine ER
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2012-02 |
| Est. Completion | 2013-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01548638
The ClinicalTrials.gov registry entry for NCT01548638 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Galantamine ER is the first listed.
NCT01548638 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01548638 about?
NCT01548638 is a clinical study titled "Effect of Galantamine on Smoking Abstinence". This is a preliminary open-label study to determine whether a medication called galantamine (Brand Name: Razadyne) will help smokers quit and whether it reduces cognitive problems that smokers experience during a quit attempt.
What is the current status of trial NCT01548638?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2012-02. Estimated completion is 2013-10.
What interventions are being tested in trial NCT01548638?
The interventions under investigation include: Galantamine ER (DRUG).
Who is sponsoring clinical trial NCT01548638?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.